WO2017208251A1 - Nouvelle forme polymorphe stable de brexpiprazole et son procédé de préparation - Google Patents
Nouvelle forme polymorphe stable de brexpiprazole et son procédé de préparation Download PDFInfo
- Publication number
- WO2017208251A1 WO2017208251A1 PCT/IN2017/050198 IN2017050198W WO2017208251A1 WO 2017208251 A1 WO2017208251 A1 WO 2017208251A1 IN 2017050198 W IN2017050198 W IN 2017050198W WO 2017208251 A1 WO2017208251 A1 WO 2017208251A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brexpiprazole
- crystalline form
- formula
- compound
- methyl
- Prior art date
Links
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229960001210 brexpiprazole Drugs 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- VMIRJNDPLCQEHB-UHFFFAOYSA-N 1-(1-benzothiophen-4-yl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=C1C=CS2 VMIRJNDPLCQEHB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 4
- 150000002941 palladium compounds Chemical class 0.000 claims description 4
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 claims description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RTFADALJKSFJDZ-UHFFFAOYSA-N n-cyclohexyl-2-piperazin-1-ylacetamide Chemical compound C1CCCCC1NC(=O)CN1CCNCC1 RTFADALJKSFJDZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- -1 benzothiophene compound Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N ethylene glycol dimethyl ether Natural products COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 2
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 2
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 2
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N Dopamine Natural products NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DPQAKBJISUNJNK-UHFFFAOYSA-N O=C1Nc2cc(OCCCCCl)ccc2C=C1 Chemical compound O=C1Nc2cc(OCCCCCl)ccc2C=C1 DPQAKBJISUNJNK-UHFFFAOYSA-N 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CCKKZUUXAAEVRO-UHFFFAOYSA-N tert-butyl 4-(1-benzothiophen-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=C1C=CS2 CCKKZUUXAAEVRO-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a new crystalline polymorph of brexpiprazole. More specifically, the invention relates to novel Form M of brexpiprazole, process for preparing the novel form of brexpiprazole and pharmaceutical formulations comprising the novel form of brexpiprazole. The present invention also relates to an improved process for the preparation of 1-(benzo[b]thiophen-4-yl)piperazine and its further use for the preparation of brexpiprazole.
- Brexpiprazole is a serotonin- dopamine activity modulator (SDA M) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder and chemically known as 7-[4-(4-(Benzo[b]thien-4-yl)-piperazin-1-yl)butoxy]-1 H-quinolin-2-one.
- SDA M serotonin- dopamine activity modulator
- WO2013015456 discloses a dihydrate of a benzothiophene compound or a salt thereof, and a process for producing the same.
- C N 104829603 discloses a crystalline form A of brexpiprazole hydrochloride and a process for preparing the same.
- Polymorphism is a typical property of some molecules, wherein the occurrence of different crystal forms is noticed.
- a single molecule may give rise to diverse polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g. measured by thermogravi metric analysis - "TGA”, or differential scanning calorimetry - “DSC”), X -ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum.
- TGA thermogravi metric analysis -
- DSC differential scanning calorimetry -
- One or more of these techniques may be used to distinguish different polymorphic forms of a compound.
- Identifying new polymorphic forms and solvates of a pharmaceutical product may provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
- New polymorphic forms and solvates of a pharmaceutical useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product.
- Another object of the present invention is to provide a new stable polymorph of brexpiprazole which is suitable for use on a commercial scale.
- Another object of the present invention is to provide an improved process for the preparation of tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-1-carboxylate.
- Another object of the present invention is to provide an improved process for the preparation of brexpiprazole using 1-(benzo[b]thiophen-4-yl)piperazine prepared by the present invention.
- Figure 1 X -ray diffraction spectrum of brexpiprazole Form M.
- the present invention comprises a new stable polymorph of brexpiprazole.
- the new polymorph of brexpiprazole is hereafter designated as ' brexpiprazole Form M _.
- crystalline Form M characterized by having an X -ray powder diffraction pattern that comprises peaks with 2 : :values (+ 0.2) of 4.19, 8.43, 9.47, 14.62, 16.91, 18.08, 19.05, 19.80, 21.33, 22.56, 24.51, 28.30 and 30.79.
- a second aspect of the present invention there is provided an improved process for the synthesis of 1-(benzo[b]thiophen-4-yl)piperazine or its salt (II)
- the present invention comprises a new stable polymorph of brexpiprazole.
- the new polymorph of brexpiprazole is hereafter designated as ' brexpiprazole Form M_.
- the term ' stable refers to brexpiprazole Form M which does not change on storage and does not require any special conditions for storage.
- Brexpiprazole Form M of the present invention is non- solvated crystalline form and is characterized by means of its characteristic X -ray diffraction pattern and DSC pattern.
- crystalline Form M of brexpiprazole According to a first aspect of the present invention, there is provided crystalline Form M of brexpiprazole.
- the crystalline Form M of the present invention have been characterized by powder X -ray diffraction spectroscopy which produces a fingerprint of the particular
- brexpiprazole Form M in accordance with the present invention is characterized by having an X -ray powder diffraction pattern that comprises peaks with 2 : :values (+ 0.2) of 4.19, 8.43, 9.47, 14.62, 16.91, 18.08, 19.05, 19.80, 21.33, 22.56, 24.51, 28.30 and 30.79.
- the crystalline polymorph Form M of brexpiprazole has an X RD pattern with peaks at 2 rvalues as shown in Table 1.
- Table 1 X RD peaks of crystalline Form M of Brexpiprazole. Position d-spacing (Al) Relative
- crystalline Form M of brexpiprazole is characterized by havi ng an X R D pattern as shown i n F igure 1.
- crystalline Form M of brexpiprazole of the present invention is characterized as having a DSC, exhibiting a significant peak at around 184eC.
- crystalline Form M of brexpiprazole of the present invention is characterized as having a DSC as shown in Figure 2.
- the brexpiprazole base used in preparing the polymorph may be obtained by methods described in the prior art which are herein incorporated by reference in their entirety.
- the brexpiprazole used as a starting material can be in any form, e.g. it can be in a reaction solution, suspension, crude or in anhydrous, hydrated or solvated form.
- Crystalline Form M of brexpiprazole may be prepared by dissolving brexpiprazole of any form or mixture of any form in a suitable solvent or solvent mixture thereof and then precipitating crystalline Form M of brexpiprazole from the solution.
- the suitable solvent is selected form alcohols such as methanol, ethanol, isopropyl alcohol, tert- butyl alcohol or n- butyl alcohol; ketones such as acetone, diethyl ketone, methyl ethyl ketone, methyl isobutyl ketone and methyl propyl ketone; esters such as ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl acetate, ethyl formate and methyl formate; chlorinated solvents such as methylene di chloride, chloroform, carbon tetrachloride and ethylene di chloride; tetrahydrofuran, methyl tert-butyl ether, di isopropyl ether, toluene, xylene and a mixture thereof.
- Preferable solvents used are mixture of alcoholic solvents and chlorinated solvents. In a most preferred embodiment the solvents used are m
- the ratio of polar to non- polar solvent may vary from 10:1 to 1 :10, preferably 1 :10.
- the reaction mass may be stirred for about 30 minutes to about 5 hours at a temperature of about 25eC to 80eC to get clear solution.
- the reaction is preferably sti rred at a temperature rangi ng from about 25eC to about 50eC .
- Precipitation can be effected by conventional means such as partial removal of solvent, lowering the temperature or by adding anti -solvent or a combination thereof.
- seeds of brexpiprazole Form M may be used during the isolation.
- reaction mixture containing the product was cooled down to a temperature of 5-151C.
- anti -solvent was added followed by stirring for prolong period of time.
- Preferable anti-solvents are n-heptane, cyclohexane, diisopropyl ether, petroleum ether and n-hexane; n-heptane being more preferable.
- the prolonged period is from about 1 hour to about days, preferably from about 1 hour to about 1 day, more preferably from about 1 hour to about 5 hours.
- the precipitated Form M may be isolated by filtration, for example by either gravity or
- the precipitate may be dried at 25-60eC and/or in vacuum to obtain crystalline
- the process of the present invention affords crystalline Form M of brexpiprazole in high purity and high yield.
- the novel crystalline Form M of brexpiprazole obtained according to the present invention is substantially free from other crystal and non-crystal forms of brexpiprazole.
- Substantially free_ from other forms of brexpiprazole shall be understood to mean that the polymorphs of brexpiprazole contain less than 10%, preferably less than 5%, of any other forms of brexpiprazole and less than 1 % of other impurities, water or solvates.
- the brexpiprazole Form M prepared according to the present invention contains less than 11 % total impurities, preferably less than 6% total impurities.
- the brexpiprazole Form M prepared according to the present invention contains less than 1 % total impurities.
- the process of the present invention affords crystalline Form M of brexpiprazole having moisture content less than 2%.
- novel form is environmentally friendly and suitable for use on a commercial scale.
- the process of invention may be used as a method for purifying any form of brexpiprazole, as well as for the preparation of the new polymorphic form M.
- the crystalline Form M of brexpiprazole obtained by the processes disclosed in the present application may be formulated as solid compositions for oral administration in the form of capsules, tablets, pills, powders or granules.
- crystalline Form M of brexpiprazole as described above for use in medicine.
- crystalline Form M of brexpiprazole as described above for use in treating schizophrenia, and as an adjunctive treatment for depression.
- crystalline M of brexpiprazole as described above for use in the manufacture of a medicament for treating schizophrenia, and as an adjunctive treatment for depression.
- a method of treating schizophrenia, and as an adjunctive treatment for depression comprising administering to a patient in need thereof a therapeutically effective amount of crystalline M of brexpiprazole as described above.
- molar ratio of compound of formula (III) to palladium compound Tris(di benzyl ideneacetone)di pal I adium(0) is about 1 :0.01, preferably is about 1 :0.005, more preferably is about 1 :0.004.
- molar ratio of compound of formula (III) to tertiary phosphine 2-Dicyclohexylphosphino-2 7 4 7 €-triisopropylbiphenyl is about 1 :0.02, preferably is about 1 :0.015, more preferably is about 1 :0.012.
- inert solvent may be selected from water; ethers such as dioxane, tetrahydrofuran, diethyl ether, di ethylene glycol dimethyl ether, and ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylene; lower alcohols such as methanol, ethanol, and isopropanol; ketones such as acetone and methyl ethyl ketone; and polar solvents such as DM F, DM SO, hexamethy I phosphoric tri amide, and acetonitrile.
- a preferred inert solvent is toluene.
- suitable base may be selected from alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; alkali metal hydrogen carbonates such as lithium hydrogencarbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate; alkali metals such as sodium and potassium; inorganic bases such as sodium amide, sodium hydride, and potassium hydride; alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, lithium tert-butoxide, sodium tert-butoxide, and potassium tert-butoxide; and organic bases such as tri ethyl amine, tri propyl amine, pyridine, quinoline, piperidine, imidazole, N- ethyldiisopropylamine, dimethyl ami nopyri din
- step (1) the mixture is heated to reflux temperature.
- step (2) deprotection of the compound obtained in step (1) is carried out under acidic condition using cone HCI.
- step (3) isolating compound (II) in form of its salt is carried out using IPA. HCI.
- step (a) optionally purifying the compound obtained in step (a).
- suitable base may be selected from alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; alkali metal hydrogencarbonates such as lithium hydrogencarbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate; alkali metals such as sodium and potassium; inorganic bases such as sodium amide, sodium hydride, and potassium hydride; alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, lithium tert-butoxide, sodium tert-butoxide, and potassium tert-butoxide; and organic bases such as tri ethyl amine, tri propyl amine, pyridine, quinoline, piperidine, imidazole, N- ethyldiisopropylamine, dimethyl ami
- suitable solvent may be selected from polar solvents such as C 1-C4 alcohols; esters such as ethyl acetate; polar aprotic solvents such as sulfolane, dimethyl formamide, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, trioxane, N- methyl pyrrol i done, dimethyl acetamide; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone, methyl vinyl ketone; nitriles such as acetonitrile, propionitrile; chlorinated organic solvents such as chloroform, dichloromethane, ethylene di chloride, hydrocarbons such as toluene, xylene, heptane, cyclohexane and the like
- the dissolution temperatures may range from about 10tC to about reflux temperature of the solvent, depending on the solvent used for dissolution.
- optionally purifying the compound obtained in step (a) may be carried out using suitable solvent may be selected from polar solvents such as C1 -C4 alcohols; esters such as ethyl acetate; polar aprotic solvents such as sulfolane, dimethyl formamide, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, trioxane, N- methyl pyrrol i done, dimethyl acetamide; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone, methyl vinyl ketone; nitriles such as acetonitrile, propionitrile; chlorinated organic solvents such as chloroform, dichloromethane, ethylene di chloride, hydrocarbons such as toluene, xylene, heptane, cyclohexane and the like or mixture thereof.
- suitable solvent may be selected from polar solvents such as C
- the dissolution temperatures may range from about 10tC to about reflux temperature of the solvent, depending on the solvent used for dissolution.
- Brexpiprazole (5 gm) was stirred in a mixture of M DC and methanol (10 vol, 9:1) at 20-25eC. The reaction mass was heated at 35-38eC and stirred further for 10 min. The reaction mass was allowed to cool slowly to 5-10eC. 15 volumes of n- heptane was added at 5- 10eC . T he reacti on mass was further sti rred at 5- 10eC for 2-3 Hrs. The solid was isolated by filtration, washed with n-heptane (10mL x 2) and dried under vacuum at 45-50eC for 15-18 hrs. The isolated solid was identified as crystalline Form M by powder X -ray diffraction pattern (Fig 1) and DSC (Fig 2).
- Boc- Piperazine 131.10 gm
- NatBuO 63.12 gm
- the mixture was heated to reflux temperature.
- T L C cool the mixture to 20eC to 25eC gradually and then cooled to 10eC-20eC.
- the solid obtained was further subjected to filtration, washed with methanol (1vol) and further dried in vacuum oven at 70eC for 12 to 16 hrs. to obtain 70gm of pure brex pi praz ol e ( 53% y i el d) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un nouveau polymorphe cristallin de brexpiprazole. Plus spécifiquement, l'invention concerne une nouvelle forme M de brexpiprazole, un procédé de préparation de la nouvelle forme de brexpiprazole et des formulations pharmaceutiques comprenant la nouvelle forme de brexpiprazole. La présente invention concerne également un procédé amélioré de préparation de 1-(benzo[b]thiophén-4-yl)pipérazine et son utilisation ultérieure pour la préparation de brexpiprazole.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621018652 | 2016-05-31 | ||
IN201621018652 | 2016-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017208251A1 true WO2017208251A1 (fr) | 2017-12-07 |
Family
ID=60479181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2017/050198 WO2017208251A1 (fr) | 2016-05-31 | 2017-05-24 | Nouvelle forme polymorphe stable de brexpiprazole et son procédé de préparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017208251A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111909159A (zh) * | 2019-05-08 | 2020-11-10 | 成都弘达药业有限公司 | 一种依匹哌唑有关物质及其制备方法 |
WO2023068253A1 (fr) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | Nouvelle forme cristalline de composé de benzothiophène et son procédé de production |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112464A1 (fr) * | 2005-04-14 | 2006-10-26 | Otsuka Pharmaceutical Co., Ltd. | Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux |
WO2013015456A1 (fr) * | 2011-07-28 | 2013-01-31 | Otsuka Pharmaceutical Co., Ltd. | Procédé de production d'un composé benzo[b]thiophène |
WO2013162046A1 (fr) * | 2012-04-23 | 2013-10-31 | Otsuka Pharmaceutical Co., Ltd. | Dihydrate de composé de benzothiophène ou de sel de celui-ci, et son procédé de production |
US20150086632A1 (en) * | 2012-04-23 | 2015-03-26 | Otsuka Pharmaceutical Co., Ltd. | Injectable Formulation |
WO2017106641A1 (fr) * | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Formes à l'état solide de brexpiprazole |
-
2017
- 2017-05-24 WO PCT/IN2017/050198 patent/WO2017208251A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112464A1 (fr) * | 2005-04-14 | 2006-10-26 | Otsuka Pharmaceutical Co., Ltd. | Benzothiophenes a substituant piperazine pour le traitement de troubles mentaux |
WO2013015456A1 (fr) * | 2011-07-28 | 2013-01-31 | Otsuka Pharmaceutical Co., Ltd. | Procédé de production d'un composé benzo[b]thiophène |
WO2013162046A1 (fr) * | 2012-04-23 | 2013-10-31 | Otsuka Pharmaceutical Co., Ltd. | Dihydrate de composé de benzothiophène ou de sel de celui-ci, et son procédé de production |
US20150086632A1 (en) * | 2012-04-23 | 2015-03-26 | Otsuka Pharmaceutical Co., Ltd. | Injectable Formulation |
WO2017106641A1 (fr) * | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Formes à l'état solide de brexpiprazole |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111909159A (zh) * | 2019-05-08 | 2020-11-10 | 成都弘达药业有限公司 | 一种依匹哌唑有关物质及其制备方法 |
WO2023068253A1 (fr) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | Nouvelle forme cristalline de composé de benzothiophène et son procédé de production |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4455064B2 (ja) | キノリン誘導体および5−ht6リガンドとしてのその使用 | |
CA2594690C (fr) | Sels d'aripiprazole | |
US8884016B2 (en) | Apixaban preparation process | |
KR101539561B1 (ko) | 목시플록사신 염산염의 합성방법 | |
US7534890B2 (en) | Process for preparing 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1H)-quinolin-2-one salt, useful as an andrenoceptor agonist | |
US9550735B2 (en) | Process for the preparation of ivacaftor and solvates thereof | |
WO2015044965A1 (fr) | Procédé de préparation du mirabégron et de sa forme alpha cristalline | |
EP2076507A2 (fr) | Imatinib base et mésylate d'imatinib et procédés pour la préparation de ceux-ci | |
WO2007010555A2 (fr) | Nouvelles formes cristallines d'hydrochlorure de moxifloxacine et procede de preparation associe | |
EP2794610B1 (fr) | Procédés et intermédiaires de préparation du pralatrexate | |
CA2711645C (fr) | Procede de preparation d'acides 8-methoxyquinolone-carboxyliques | |
US20040242556A1 (en) | Novel crystalline form of cefdinir | |
WO2017208251A1 (fr) | Nouvelle forme polymorphe stable de brexpiprazole et son procédé de préparation | |
US8952179B2 (en) | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy} benzamide hydrochloride and pharmaceutical compositions containing it | |
US20170320862A1 (en) | Process for the preparation of brexpiprazole and intermediates thereof | |
US10023526B2 (en) | Process for the preparation of lomitapide | |
EP2260024B1 (fr) | Procédé de fabrication de [phénylsulfanylphényl] pipéridines | |
AU2007309558B2 (en) | Crystal modifications -3- (1H-indol-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-dione | |
US20190010145A1 (en) | Process for the preparation of quinolin-2(ih)-one derivatives | |
EP3374349A1 (fr) | Procédé de préparation d'eltrombopag olamine | |
Moskalenko et al. | Synthesis of N-arylmethyl-3-azabicyclo [3.3. 1] nonan-9-ones. | |
US20090131658A1 (en) | Process for preparing Olanzapine form I | |
AU2008267704A1 (en) | Improved processes for the synthesis of olanzapine | |
BRPI0707161A2 (pt) | produção de cabergolina e suas novas formas polimórficas | |
WO2012001357A1 (fr) | Forme cristalline de la prulifloxacine et procédés pour sa préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17806036 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17806036 Country of ref document: EP Kind code of ref document: A1 |